A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need

Projektinformationen

ATx201

ID Finanzhilfevereinbarung: 736508

DOI 10.3030/736508

Abgeschlossenes Projekt

EK-Unterschriftsdatum 11 Juli 2016

Startdatum 1 August 2016

Enddatum 30 November 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

UNION THERAPEUTICS AS
Denmark

Ziel

AntibioTx is advancing a chemical class of compounds to be approved and used for the first time to treat bacterial infections. The class is based on an easy to synthesize chemical scaffold, which enables broad applicability across topical and systemic indications. AntibioTx discovered that compounds from this class overcome current resistance problems such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci and resistance towards all topical antibiotics. The class also exhibits extraordinarily strong ability to delay the onset of de novo resistance compared to marketed antibiotics. Finally, the compound class benefits from a proven human safety profile due to decades of safe oral use for non-bacterial purposes. The antibacterial properties of the class are novel and have been patent protected by AntibioTx. ATx201 is a lead candidate from this novel class of antibiotics and has the potential to fundamentally change thel approach to managing dermatological infections by providing an effective topical alternative to systemic treatments. ATx201 is being developed for treatment of infected atopic dermatitis a disease affecting >50 million patients worldwide associated with significant comorbidity. The market for treatment of infected atopic dermatitis is characterized by off-label use of topical and systemic antibiotics. Topical treatment is preferred by physicians; however, antibiotic resistance is rendering the leading topical antibiotics ineffective. As a result patients and physicians are seeking alternative treatments. ATx201 has substantial competitive advantages to current leading topical antibiotics. In particular ATx201 benefits from a wide spectrum of effect and very favourable resistance evolution properties.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › dermatology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

UNION THERAPEUTICS AS

• Netto-EU-Beitrag: € 50 000,00
• Adresse: TUBORG HAVNEVEJ 18 ; 2900 HELLERUP ; Dänemark
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Danmark › Hovedstaden › Københavns omegn
• Region: Danmark › Hovedstaden › Københavns omegn
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00